Use and abuse of flunitrazepam

Area of Science:

• Pharmacology
• Public Health
• Drug Policy

Background:

• Flunitrazepam is a potent benzodiazepine not approved for medical use in the United States.
• Its importation and possession are illegal within the US.
• Existing benzodiazepines offer comparable therapeutic benefits without the associated illicit use profile.

Purpose of the Study:

• To evaluate the therapeutic advantages of Flunitrazepam compared to currently marketed benzodiazepines in the US.
• To assess the public health risks associated with Flunitrazepam's illicit use.
• To review measures implemented to control its abuse.

Main Methods:

• Literature review of pharmacological properties and clinical uses of Flunitrazepam.
• Analysis of drug enforcement and public health data related to Flunitrazepam.
• Comparative assessment of Flunitrazepam's risk profile against other benzodiazepines.

Main Results:

• Flunitrazepam demonstrates no clear therapeutic advantage over US-marketed benzodiazepines.
• Its rapid sedation, amnesia-inducing effects, and potentiation with alcohol contribute to its misuse.
• Reported illicit uses include "party drug," "club drug," and "date rape drug" scenarios.
• Various control measures have been enacted to mitigate its illegal distribution and use.

Conclusions:

• Flunitrazepam's lack of therapeutic benefit in the US, coupled with its high potential for abuse, supports its restricted status.
• The drug's association with recreational and criminal activities necessitates ongoing monitoring and control strategies.
• Further research is required to definitively ascertain if Flunitrazepam presents a greater public health risk than other benzodiazepines.